Generic Biologics? Not Yet

Sellers, L.J.
October 2003
Pharmaceutical Executive;Oct2003, Vol. 23 Issue 10, p18
Trade Publication
Reports on the statement by Martin Harvey Allchurch, spokesperson for the European Agency for the Evaluation of Medicinal Products, that the story in the "New York Times" about Omnitrop somatropin biogeneric is not true. Comments on Novartis/Sandoz' application for the marketing of Omnitrop i Europe; U.S. Food and Drug Administration's statement that somatropin is not a biologic.


Related Articles

  • The quest for generic biotechnology pharmaceuticals in the USA. Kowalski, Thomas J.; Fekete, Pamela; Yvon, Anne-Marie C. // Journal of Commercial Biotechnology;Apr2005, Vol. 11 Issue 3, p271 

    As patent protection expires on the first generation of biotechnology products, such as human growth hormone and erythropoietin, there is an impetus for the development and marketing of generic equivalents. Currently there is no statutory or regulatory framework governing generic biotechnology...

  • Price and Prejudice. Bush, Laura // BioPharm International;Dec2005, Vol. 18 Issue 12, p12 

    The article presents the author's views on biasness in the field of biologics. It is reported that at a meeting of the American Association of Pharmaceutical Scientists, presenter Art Mlodozeniec claimed that if he brought up human growth hormone and said that the processes and impurities were...

  • Can There Be Abbreviated Applications, Generics, or Follow-On Products? Webster, Christopher; Copmann, Thomas; Garnick, Robert; Green, James; Hayes, Mark; Landis, John; Lubiniecki, Anthony; Murano, Genesio; Seamon, Kenneth; Zezza, Diane; Woollett, Gillian R. // BioPharm International;Jul2003, Vol. 16 Issue 7, p28 

    Presents questions and answers advisory on generic biologics. Definition of biologic; Meaning of generic biologics; Importance of follow-on biologics to the innovator industry.

  • Biosimilars Market Presents Tough Challenges.  // Chain Drug Review;11/19/2012, Vol. 34 Issue 20, p61 

    The article presents the views of Claudio Albrecht, chief executive officer of Actavis Group hf, on biosimilars market related issues surrounding the companies that create biotech drugs and the generic drug industry.

  • Biosimilars could save $US billions.  // PharmacoEconomics & Outcomes News;Nov2014, Vol. 716 Issue 1, p1 

    The article discusses a report from nonprofit research institute Rand Corp., which examines the cost savings potential of biosimilars or generic versions of biologicals used in treating various medical conditions until 2024 in the U.S.

  • Biogenerics Setback. Houlton, Sarah // Pharmaceutical Executive;May2004, Vol. 24 Issue 5, p42 

    Reports that the European Union's European Commission has refused to grant marketing approval for Omnitrop, a generic version of the human growth hormone, somatotropin, developed by Sandoz. Claim that the performance of compatibility studies implied that the legal conditions for the application...

  • Sign of Things to Come? Houlton, Sarah // Pharmaceutical Executive;Feb2006, Vol. 26 Issue 2, p50 

    The article reports that the European Medicines Agency (EMEA) intends to complete its guidelines for the approval of generic copies of biologic medicines in early 2006. The approval of biogenerics could be a potential business opportunity for generic companies. The initial guidelines are...

  • BIO response to December editorial. Greenwood, Jim // Nature Biotechnology;Feb2014, Vol. 32 Issue 2, p131 

    A letter to the editor in response to the article which discusses the role of Biotechnology Industry Organization in the U.S. in establishing the pathway for the approval of biosimilars and also provide information on treating the biosimilars as generic drugs.

  • GENERIC DRUG TRENDS Generics "Pipeline" Predicts Continued Market Share Gains Through 2014. Buffery, Dalia // American Health & Drug Benefits;Nov/Dec2010, Vol. 3 Issue 6, p391 

    The article focuses on a forecast of increased marked share for generic drugs in the U.S. through 2014. It states a number of top-selling drugs including the statins Lipitor and Crestor and the gastrointestinal drug Nexium will have patents expire by 2014. It mentions the expiration of patent...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics